Q-METOPROLOL (TYPE L) TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

METOPROLOL TARTRATE

থেকে পাওয়া:

QD PHARMACEUTICALS ULC

এটিসি কোড:

C07AB02

INN (আন্তর্জাতিক নাম):

METOPROLOL

ডোজ:

100MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

METOPROLOL TARTRATE 100MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

100/1000

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

BETA-ADRENERGIC BLOCKING AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0111923003; AHFS:

অনুমোদন অবস্থা:

CANCELLED PRE MARKET

অনুমোদন তারিখ:

2015-08-21

পণ্য বৈশিষ্ট্য

2
PRODUCT MONOGRAPH
PR
Q-METOPROLOL (TYPE L)
(Metoprolol Tartrate Tablets, USP)
25 mg, 50 mg and 100 mg tablets
β-Adrenergic Receptor Blocking Agent
QD PHARMACEUTICALS ULC
Date of Revision:
85 Advance Rd.
February 13, 2014
Etobicoke, Ontario
M8Z 2S6
Control Number: 171448
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
10
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................
17
OVERDOSAGE
.......................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 21
STORAGE AND STABILITY
.................................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 25
PART II: SCIENTIFIC INFORMATION
....................................................................................
25
PHARMACEUTICAL INFORMATION
.................................................................................
25
CLINICAL TRIALS
........................................................................................................